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Background-—Patients with dilated cardiomyopathy (DCM) may present with ventricular arrhythmias early in the disease course,
unrelated to the severity of left ventricular dysfunction. These patients may be classiﬁed as having an arrhythmogenic DCM (AR-
DCM). We investigated the phenotype and natural history of patients with AR-DCM.
Methods and Results-—Two hundred eighty-ﬁve patients with a recent diagnosis of DCM (median duration of the disease 1 month,
range 0 to 7 months) and who had Holter monitoring at baseline were comprehensively evaluated and followed for 107 months
(range 29 to 170 months). AR-DCM was deﬁned by the presence of ≥1 of the following: unexplained syncope, rapid nonsustained
ventricular tachycardia (≥5 beats, ≥150 bpm), ≥1000 premature ventricular contractions/24 hours, and ≥50 ventricular couplets/
24 hours, in the absence of overt heart failure. The primary end points were sudden cardiac death (SCD), sustained ventricular
tachycardia (SVT), or ventricular ﬁbrillation (VF). The secondary end points were death from congestive heart failure or heart
transplantation. Of the 285 patients, 109 (38.2%) met criteria for AR-DCM phenotype. AR-DCM subjects had a higher incidence of
SCD/SVT/VF compared with non–AR-DCM patients (30.3% vs 17.6%, P=0.022), with no difference in the secondary end points.
A family history of SCD/SVT/VF and the AR-DCM phenotype were statistically signiﬁcant and cumulative predictors of SCD/SVT/VF.
Conclusions-—One-third of DCM patients may have an arrhythmogenic phenotype associated with increased risk of arrhythmias
during follow-up. A family history of ventricular arrhythmias in DCM predicts a poor prognosis and increased risk of SCD. ( J Am
Heart Assoc. 2015;4:e002149 doi: 10.1161/JAHA.115.002149)
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I n patients with dilated cardiomyopathy (DCM), ventriculararrhythmias may occur in the absence of signs and
symptoms of overt heart failure and may not be related to the
severity of left ventricular (LV) dysfunction. An arrhythmo-
genic trait associated with increased risk of sudden cardiac
death (SCD) is well known in cardiomyopathies such as
arrhythmogenic right ventricular (RV) cardiomyopathy (ARVC)
and left-dominant arrhythmogenic cardiomyopathy,1,2 as well
as in hypertrophic cardiomyopathy3 and LV noncompaction,4–7
and is used for the purpose of risk stratiﬁcation. However, the
speciﬁc criteria for “arrhythmogenic” DCM (AR-DCM) are
lacking. As a consequence, in DCM, clinicians often face
challenges in the appropriate selection of candidates for an
implantable cardioverter-deﬁbrillator (ICD) for the prevention
of SCD in the presence of an arrhythmogenic proﬁle or
positive family history of SCD or rapid ventricular tachycardia
in the absence of heart failure or signiﬁcant LV dysfunction.
We investigated the arrhythmogenic phenotype in a large
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cohort of DCM patients, based on speciﬁc diagnostic criteria,
to better understand the prevalence, natural history, and
prognostic implications of AR-DCM.
Methods
Study Population
We analyzed 285 patients with a recent diagnosis of DCM (the
median duration of the disease was 1 month [range 0 to
7 months]) who were prospectively enrolled in our Familial
Cardiomyopathy Registry and who had 24-hour Holter mon-
itoring data within 12 months from enrollment. We excluded
183 patients for whom a baseline Holter monitoring was
either never performed or performed >1 year from enroll-
ment. The enrollment period was from 1991 to 2012.
Informed consent was obtained from all enrolled subjects,
and the respective institutional review committees approved
the study. Enrolled patients had a physical examination,
electrocardiogram, echocardiogram, and laboratory investiga-
tions performed according to published guidelines.8–10
None of the patients was treated with amiodarone at the
time of Holter monitoring. Additional clinically indicated
studies were performed, including right- and left-side heart
catheterization, ventriculography, coronary angiography,
endomyocardial biopsy, and neuromuscular evaluation.
Clinical Deﬁnitions
Criteria for the diagnosis of DCM were the presence of LV
fractional shortening <25% and/or LV ejection fraction (LVEF)
<45%, and LV end-diastolic dimensions (LVEDD) >117% of the
predicted value based on the Henry formula.8,11
Exclusion criteria included arterial hypertension (>140/
90 mm Hg),12 coronary artery disease (obstruction >50% of
the luminal diameter in a major branch by coronary angiog-
raphy), history of chronic excess alcohol consumption
(>100 g/d), tachycardia-induced cardiomyopathy, systemic
diseases affecting short-term prognosis, pericardial disease,
congenital heart disease, and cor pulmonale.8,13
Familial DCM was deﬁned by the presence of ≥2 family
members affected by DCM.8–10 AR-DCM phenotype was
diagnosed by the presence of 1 of the following: (1)
unexplained syncope (likely due to ventricular tachyarrhyth-
mia),2,14–16 (2) rapid nonsustained ventricular tachycardia
(NSVT) deﬁned as ≥5 consecutive ventricular beats,17 lasting
<30 seconds, with a rate ≥150/min on 24-hour Holter
monitoring,18 (3) ≥1000 premature ventricular contractions
(PVCs) in 24 hours1 or (4) ≥50 couplets in 24 hours.19 ICD
implantation had been performed for primary prevention in
selected patients with DCM considered at high risk for SCD
(ie, persistent LV dysfunction with LVEF ≤35% and New York
Heart Association class II or III while being treated with
optimal medical therapy).
End points
The primary end point was the occurrence of SCD or rapid and
sustained ventricular arrhythmias. Speciﬁcally, SCD was
deﬁned as witnessed sudden cardiac death with or without
documented ventricular ﬁbrillation (VF) or death within 1 hour
of acute symptoms or nocturnal death with no antecedent
history of immediate worsening symptoms. Ventricular
arrhythmias were deﬁned as sustained (≥30 seconds, hemo-
dynamically symptomatic) ventricular tachycardia (SVT), VF,
appropriate SVT or VF treatment with implantable car-
dioverter-deﬁbrillator (ICD) (shock or antitachycardia pacing
for termination of SVT ≥185 bpm), cardiopulmonary resusci-
tation after cardiac arrest, or SCD.14 The secondary end point
was death due to heart failure (excluding SCD) or heart
transplantation. A history of familial SCD was considered to
be present if at least 1 family member (up to third degree)
died suddenly at age younger than 60 years.14
Statistical Analysis
Clinical and demographic characteristics were compared by
using the v2 test for discrete variables expressed as
proportions (or the Fisher exact test when necessary), the
ANOVA test for continuous parameters, and the Brown–
Forsythe statistic when the assumption of equal variances did
not hold. The nonparametric median test was used when
appropriate. For the time-to-event analysis, we started from
the date of birth until events or censoring.1,20–22 Patients with
no events were censored at the date of the last available
follow-up.
Cause-speciﬁc event-free survival curves for SCD/SVT/VF
and heart failure death (excluding SCD)/heart transplantation
were estimated and plotted by using the Kaplan–Meier
method, and the log-rank test was applied to investigate for
differences in survival. Cox regression analysis was then used
to identify predictors for the SCD or malignant ventricular
arrhythmias end point.
To mark the family code as a cluster indicator in the Cox
model, we used the “cluster” argument of the “coxph”
function in R: this is a special function used in the context of
survival models. It identiﬁes correlated groups of observations
and is used on the right hand side of the formula. Use of the
argument “cluster” in the survival model implies that robust
sandwich variance estimators are calculated (the resulting
variance is what is known as the “working independence”
variance in a GEE model). The proportional hazards assump-
tion of the Cox model was veriﬁed by using the Grambsch–
Therneau test.23 Hazard ratios and 95% CIs were calculated;
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variables reaching P<0.05 at univariable analysis were
included in the multivariable model. Statistical analyses were
performed with use of the IBM SPSS Statistical Package 20.0
and the R statistical package version 2.14.1. A P value of
≤0.05 was considered statistically signiﬁcant.
Results
Prevalence and Phenotype of AR-DCM
Of 285 DCM patients with Holter monitor data at baseline,
109 (38.2%) fulﬁlled the prespeciﬁed diagnostic criteria of AR-
DCM. One hundred thirty (45.6%) subjects had a familial
history of DCM: 71 patients were clustered in 30 families,
with an average of 2.4 individuals per family (median of 2),
and 59 were the only family members studied. The remaining
155 patients were sporadic “nonfamilial” cases. Table 1
shows the arrhythmogenic proﬁle of AR-DCM patients.
Table 2 shows the baseline characteristics of AR-DCM versus
non–AR-DCM patients. No signiﬁcant clinical, echocardio-
graphic or electrocardiographic difference was found between
the 2 groups. None of the patients had signiﬁcant RV
involvement or sufﬁcient criteria to fulﬁll the 2010 revised
criteria for ARVC.24
Natural History of the AR-DCM Phenotype
During long-term follow-up (median 107 months, range 29 to
170 months), a greater number of AR-DCM patients had
SCD/SVT/VF (33/109 cases, 30.3%) than did non–AR-DCM
patients (31/176, 17.6%). They also had worse event-free
long-term survival when considering SCD/SVT/VF, as shown
in Figure 1A (P=0.02). There was no signiﬁcant difference
between AR-DCM (23/109, 21.1%) and non–AR-DCM (37/
176, 21%) patients regarding the secondary end points of
heart failure death or heart transplantation (Figure 1B,
P=0.948). When using the date of enrollment in the registry
for survival analysis, the SCD/SVT/VF survival curves for AR-
DCM and non–AR-DCM diverged and became signiﬁcantly
different during follow-up (P=0.001 at 100 months), as shown
in Figure 2.
A total of 85 (29.8%) of 285 study patients―45 (41%) of
109 AR-DCM and 40 (23%) of 176 non–AR-DCM patients―re-
ceived an ICD during follow-up (P=0.001). Of these, 25
patients experienced ICD therapy during the follow-up. There
was a trend toward a higher number of patients who received
≥1 appropriate ICD therapy during follow-up in the AR-DCM
cohort compared with non–AR-DCM: 35.6% (n=16) versus
22.5% (n=9), respectively (P=0.19).
In the AR-DCM cohort, there were no signiﬁcant differ-
ences in the incidence of SCD/SVT/VF between patients with
LVEF ≤35% and >35% at enrollment: 31.2% (20/64 events)
and 28.9% (13/45 events), respectively; P=0.79. Of 285
subjects, 73 (25.6%)―36 AR-DCM and 37 non–AR-
DCM―had an LVEF between 35% and ≤45% at enrollment.
Of these, 15 subjects had SCD or SVT/VF: 30.1% (n=11) AR-
DCM and 10.8% (n=4) non–AR-DCM (P=0.037).
Prognostic Impact of AR-DCM Phenotype
Table 3 shows the results of the univariable and multivariable
analysis of the association with SCD or SVT/VF in the overall
DCM population. The AR-DCM phenotype (hazard ratio 1.81,
95% CI 1.10 to 2.97, P=0.02) and a positive family history of
SCD or SVT/VF (hazard ratio 2.21, 95% CI 1.04 to 4.66,
P=0.038) were identiﬁed as the only early signiﬁcant predictors
Table 1. Arrhythmic Proﬁle of 109 AR-DCM Patients
Criteria AR-DCM Patients, n (%)
NSVT (≥5 beats, ≥150 bpm) 43 (39.4)
≥1000 PVCs/24 h 90 (82.6)
≥50 Couplets/24 h 40 (36.7)
Syncope 8 (7.3)
AR-DCM indicates arrhythmogenic dilated cardiomyopathy; NSVT, nonsustained
ventricular tachycardia; PVCs, premature ventricular contractions.
Table 2. Comparison of Clinical and Instrumental
Characteristics at Enrollment of AR-DCM and Non–AR-DCM
Patients
Baseline Characteristics
AR-DCM
(n=109)
Non–AR-DCM
(n=176)
P
Value*
Male sex, n (%) 76 (69.7) 126 (71.6) 0.736
Age at diagnosis, y 4113 4114 0.955
LVEDD, mm 6610 6511 0.476
LVEF, % 3411 3214 0.425
Complete LBBB, n (%) 22 (20.2) 47 (26.7) 0.222
Complete RBBB, n (%) 4 (3.7) 7 (4) 1.000
Inverted T waves in leads V2 to
V3, n (%)
2 (1.8) 7 (4) 0.490
QRS >110 ms in leads V1 to
V3, n (%)
36 (33) 66 (37.5) 0.468
Family history of SCD/SVT/VF,
n (%)
11 (10.1) 14 (7.9) 0.535
b-Blocker therapy, n (%) 99 (90.8) 153 (86.9) 0.527
ACEI therapy, n (%) 88 (80.7) 138 (78.4) 0.843
AR-DCM indicates arrhythmogenic dilated cardiomyopathy; LBBB, left bundle branch
block; LVEDD, left ventricular end-diastolic diameter; LVEF, left ventricular ejection
fraction; RBBB, right bundle branch block; SCD/SVT/VF, sudden cardiac death,
sustained ventricular tachycardia, and ventricular ﬁbrillation; ACEI, angiotensin-
converting enzyme inhibitor.
*Between groups.
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for SCD or SVT/VF in the overall DCM population. Table 4
shows the cross-tabulation of family history of SCD/SVT/VF
versus AR-DCM (v2 P=0.535).
These 2 variables showed an additive prognostic effect on
the arrhythmic risk (Figure 3, Table 3) The P value of the
proportional hazard test (PH) for the Cox model was 0.23. The
P value for family history of SCD/SVT/VF was 0.65, and the P
value for AR-DCM was 0.09, indicating a trend of nonpropor-
tionality of the hazards for the AR-DCM effect.
Baseline LVEF, LVEDD, male gender, family history of DCM
or AR-DCM, inverted T waves in leads V1 to V3, QRS >110 ms
in leads V1 to V3, complete right bundle branch block, and
complete left bundle branch block were not signiﬁcantly
related to the long-term risk of SCD or ventricular arrhyth-
mias.
Finally, we examined if each of the arrhythmic criteria used
to deﬁne AR-DCM (NSVT, >1000 PVCs/24 h, >50 ventricular
couplets/24 h at Holter monitoring, history of unexplained
syncope) had different prognostic signiﬁcance in the AR-DCM
subgroup. The cumulative effect of having 1, 2, 3, or 4 criteria
was not signiﬁcant (Figure 4).
Discussion
Phenotype and Prevalence of AR-DCM
This was a study of a subset of DCM patients with a
prominent arrhythmic phenotype (arrhythmogenic DCM or AR-
DCM), in the early stages of the disease, characterized by
frequent ventricular arrhythmias and unexplained syncope in
the absence of overt heart failure. In our large DCM study
A B
Figure 1. Kaplan–Meier event-free survival. Comparison of (A) SCD/SVT/VF-free survival (primary end point) and (B) D/HTx-free survival
(secondary end point) between AR-DCM patients and non–AR-DCM patients. AR-DCM patients have a greater risk of life-threatening arrhythmic
events compared with the other DCM patients (P=0.02). Follow-up from birth to end point/last follow-up evaluation. Survival rates (as percentage
of patients at risk) are provided at ages 25, 50, and 75 years. AR-DCM indicates arrhythmogenic dilated cardiomyopathy; D/HTx, heart failure
death (excluding SCD)/heart transplant; SCD/SVT/VF, sudden cardiac death, sustained ventricular tachycardia, and ventricular ﬁbrillation.
Figure 2. Kaplan–Meier event-free survival. Comparison of
SCD/SVT/VF -free survival (primary end point) between AR-
DCM patients and non–AR-DCM patients. With the progress of
follow-up, AR-DCM patients have a greater risk of ventricular
arrhythmic events compared with to the other DCM patients
(P=0.001 at 100 months). Follow-up from enrollment/last follow-
up evaluation. AR-DCM indicates arrhythmogenic dilated car-
diomyopathy; SCD/SVT/VF, sudden cardiac death, sustained
ventricular tachycardia, and ventricular ﬁbrillation.
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cohort, extensively investigated and followed for >20 years,
the prevalence of the AR-DCM phenotype was approximately
one-third of the overall DCM population. Therefore, an
arrhythmogenic phenotype occurs in a sizable proportion of
DCM patients. The long-term natural history of AR-DCM was
characterized by a signiﬁcantly higher rate of major arrhyth-
mic events (SCD, SVT, VF), compared with the other DCM
patients. The “AR-DCM phenotype” and the family history of
SCD or SVT/VF were found to be prognostic factors useful in
the risk stratiﬁcation of DCM patients, with an additive
prognostic effect on the arrhythmic risk. Indeed, as illustrated
in Figure 2, the risk of SCD/SVT/VF in the AR-DCM group
increased over time.
Interestingly, the prognosis of AR-DCM was not related to
the severity of LV dysfunction and LV dilatation. When we
Table 3. Cox Univariable and Multivariable Analysis for SCD/SVT/VF in the Entire Study Population (285 Patients)
Univariable Analysis Multivariable Analysis
HR 95% CI P Value* HR 95% CI P Value*
AR-DCM 1.77 1.08–2.91 0.024 1.81 1.10–2.97 0.020
Family history of SCD/SVT/VF 2.11 1.00–4.45 0.049 2.21 1.04–4.66 0.038
Male sex 1.64 0.91–2.97 0.102
LVEF, % 0.99 0.97–1.02 0.74
LVEDD, mm 1.02 0.99–1.04 0.20
Inverted T waves in leads V2 to V3 0.51 0.70–3.78 0.50
QRS >110 ms in leads V1 to V3 0.73 0.44–1.22 0.23
Family history of DCM 1.35 0.83–2.22 0.23
Family history of AR-DCM 1.12 0.62–2.03 0.71
Complete LBBB 0.61 0.34–1.11 0.11
Complete RBBB 0.88 0.21–3.63 0.86
SCD/SVT/VF indicates sudden cardiac death, sustained ventricular tachycardia, and ventricular ﬁbrillation; HR, hazard ratio; AR-DCM, arrhythmogenic dilated cardiomyopathy; LVEDD, left
ventricular end-diastolic diameter; LVEF, left ventricular ejection fraction; LBBB, left bundle branch block; RBBB, right bundle branch block;.
*Between groups.
Table 4. Cross-Tabulation of Family History of SCD/
Ventricular Arrhythmias Versus AR-DCM
Family History of
SCD/SVT/VF
TotalYes No
AR-DCM
Yes Number 11 98 109
% with family history
of SCD/SVT/VF
44% 37.7% 38.2%
No Number 14 162 176
% with family history
of SCD/SVT/VF
56% 62.3% 61.8%
Total Number 25 260 285
% with family history
of SCD/SVT/VF
100% 100% 100%
AR-DCM indicates arrhythmogenic dilated cardiomyopathy; SCD/SVT/VF, sudden
cardiac death, sustained ventricular tachycardia, and ventricular ﬁbrillation.
Figure 3. Cox-estimated SCD/ventricular arrhythmias–free sur-
vival stratiﬁed by 2 risk factors. Cox-estimated SCD/SVT/VF-free
survival stratiﬁed by 2 risk factors, family history of SCD or
ventricular arrhythmias and AR-DCM diagnosis, in the overall
DCM population (285 patients). The AR-DCM phenotype (hazard
ratio 1.81, 95% CI 1.10–2.97, P=0.02) and family history of SCD
or ventricular arrhythmias (hazard ratio 2.21, 95% CI 1.04–4.66,
P=0.038) show an additive prognostic effect on mortality for
arrhythmic events. AR-DCM indicates arrhythmogenic dilated
cardiomyopathy; SCD/SVT/VF, sudden cardiac death, sustained
ventricular tachycardia, and ventricular ﬁbrillation.
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stratiﬁed the AR-DCM cohort by LVEF ≤35% and LVEF >35%,
there were no signiﬁcant differences in the risk of SCD/SVT/
VF. Neither LVEF nor LVEDD was a predictor of SCD or SVT/
VF in the multivariable analysis. In addition, in the subset of
our patients with LVEF between 35% and 45%, AR-DCM
patients had a higher incidence of major arrhythmic events
(SCD/SVT/VF) compared with non–AR-DCM subjects, thus
reinforcing the concept that AR-DCM may be associated with
SCD even in those patients with only mild systolic dysfunc-
tion. AR-DCM was not associated with poorer long-term
prognosis due to nonarrhythmic events, including death due
to heart failure and heart transplantation. These ﬁndings
suggest that subjects with AR-DCM phenotype represent a
distinct subset of DCM patients, rather than a different stage
of the disease. In fact, the AR-DCM phenotype shows
similarities and overlap with other arrhythmogenic cardiomy-
opathies, such as left dominant arrhythmogenic cardiomy-
opathy and arrhythmogenic right ventricular (RV)
cardiomyopathy.1,25
Prognostic Role of Family History
Another predictor of long-term life-threatening arrhythmic
events identiﬁed in our study was a family history of SCD or
ventricular arrhythmias. This ﬁnding emphasizes the impor-
tance of the systematic multigenerational analysis of family
history in DCM.8,10 Although the role of family history is well
established in other genetically determined arrhythmogenic
cardiomyopathies and represents an important element for
risk stratiﬁcation, management, and decision-making, this
ﬁnding is novel in DCM and may represent an important risk
factor for the primary prevention of SCD.1,2,25
Diagnostic Criteria of AR-DCM
The inclusion criteria of the AR-DCM cohort used in our study
(Table 1) were stringent, based on other investigations in
comparable study populations. The duration of NSVT is an
established risk factor of major arrhythmic events and SCD in
DCM. Grimm et al found that NSVT with a duration of
≥5 beats was signiﬁcantly associated with increased risk of
major arrhythmic events including SCD.17 Furthermore, the
heart rate in NSVT has been arbitrary,26–28 ranging from ≥100
to 150 bpm, and not associated with increased risk of life-
threatening arrhythmias and SCD in DCM.17,18,29 In our study,
we arbitrarily deﬁned NSVT as ≥5 consecutive ventricular
premature beats with a rapid heart rate (≥150 bpm), corre-
sponding to the median ventricular rate previously reported in
our DCM population.29 The deﬁnition of PVCs >1000/24 h
and ventricular couplets were based on the experience with
left-dominant arrhythmogenic cardiomyopathy.1 In our inclu-
sion criteria for AR-DCM, as in previous studies on
laminopathies,14 we included a history of syncope, an
established risk factor for major arrhythmic events in ARVC30
and hypertrophic cardiomyopathy.31,32
Clinical Implications
Our results suggest that in DCM, an accurate family history is
important not only for diagnostic purposes8,9 but also for
improved prognostic assessment. In DCM, a family history of
SCD/SVT/VF is associated with an increased risk of life-
threatening arrhythmias, a concept well established in other
forms of arrhythmogenic cardiomyopathies such as ARVC33,34
and hypertrophic cardiomyopathy.32,35 Even though none of
our AR-DCM patients fulﬁlled new task force criteria of
ARVC24 with LV involvement, the potential overlap with
desmosomal diseases (ARVC, arrhythmogenic cardiomy-
opathy, left-dominant arrhythmogenic cardiomyopathy),
considered to be distinct disorders,10 warrants further
investigations.36
Our ﬁndings support the use of systematic Holter moni-
toring in DCM for a more accurate phenotypic characteriza-
tion to improve the prognostic stratiﬁcation.
DCM patients with both an arrhythmogenic phenotype and
a family history of SCD or ventricular arrhythmias are the
Figure 4. Kaplan–Meier SCD/ventricular arrhythmias–free sur-
vival. Kaplan–Meier SCD ventricular arrhythmias–free survival
stratiﬁed by AR-DCM criteria in the AR-DCM population (109
patients). The cumulative effect of having 1, 2, 3, or 4 AR-DCM
criteria (NSVT ≥5 beats and ≥150 bpm; PVCs ≥1000/24 h;
ventricular couplets ≥50/24 hours; syncope) is not signiﬁcant.
AR-DCM indicates arrhythmogenic dilated cardiomyopathy; NSVT,
nonsustained ventricular tachycardia; PVCs, premature ventricular
contractions; SCD/SVT/VF, sudden cardiac death, sustained
ventricular tachycardia, and ventricular ﬁbrillation.
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highest risk group and should be considered candidates for
careful follow-up and possibly for ICD implantation for primary
prevention, regardless of their LVEF or LVEDD.15 In our study,
the risk of arrhythmic events was associated with these risk
factors and signiﬁcantly increased when they were combined
(see Figure 3).
Study Limitations and Future Perspectives
The prevalence of AR-DCM in our study may be overesti-
mated because we enrolled patients with familial or
suspected familial DCM, and we analyzed only patients
who had baseline Holter monitoring. However, the preva-
lence of AR-DCM in the Italian subcohort, where Holter
monitoring was systematically performed at baseline and
during follow-up, was not signiﬁcantly different (96/244
patients, 39%).
Patients excluded from the study because of the lack of
baseline Holter monitoring (n=183) had slightly less severe
DCM in terms of LV dysfunction, dilatation, and dyssynchrony
(Table 5). However, these differences seem clinically mar-
ginal.13
Patients with an arrhythmogenic phenotype may be more
likely to receive an ICD and ICD therapies are known to
exceed the number of observed sudden deaths. Antitachy-
cardia pacing as a surrogate of arrhythmic death is contro-
versial. In our study population, of 25 ICD therapies, only 4
were antitachycardia pacing and preceded an arrhythmic
storm in 1 case. In the remaining 3 cases, antitachycardia
pacing treatment was for rapid and prolonged episodes of
sustained VT (>185 bpm), consistent with potentially life-
threatening arrhythmias.
Special investigations, such with cardiac magnetic reso-
nance, were not systematically available due to the extended
enrollment period (1991–2012). The origin of ventricular
arrhythmias, from either the left ventricle or right ventricle,
could not be fully evaluated due to incomplete availability of
data on their morphology. The deﬁnition of family history of
SCD or rapid sustained ventricular arrhythmias (which
included up to third-degree relatives younger than age 60)
could have introduced a bias due to nonfamilial/genetic
causes, such as coronary heart disease.
The limited availability of genotyping data prevented
analysis of the prognostic implications of speciﬁc gene
mutations in the natural history of AR-DCM. Large-scale
genotype–phenotype association studies are ongoing to
conﬁrm our observations. Endomyocardial biopsy was not
systematically performed in this DCM cohort. Further studies
should address the potential risk stratiﬁcation differences in
ﬁbrosis, inﬂammation, and fat inﬁltration between AR-DCM
and non–AR-DCM patients. Finally, the study population was
enrolled in tertiary referral centers for cardiomyopathies and
heart failure, potentially introducing a selection bias that
limits the generalizability of extending our data to the general
DCM population.
Conclusions
We have studied a speciﬁc subgroup of DCM patients with a
predominant arrhythmogenic phenotype, AR-DCM. Our
results indicate that AR-DCM is frequent and is characterized
by a high risk of life-threatening arrhythmias, while the long-
term incidence of heart failure and heart transplantation
appears comparable to that of other DCM patients. Based on
Table 5. Comparison of Clinical and Instrumental Characteristics at Enrollment of Our Study Population and Patients Excluded
From the Study Because of the Lack of Baseline Holter Monitoring Data
Baseline Characteristics
Our Study Population
(n=285)
Patients Excluded From
the Study (n=183) P Value*
Male sex, n (%) 202 (70.9) 103 (56.3) 0.001
Age at diagnosis, y 4114 4316 0.177
LVEDD, mm 6610 6111 <0.001
LVEF, % 3313 3614 0.007
Complete LBBB, n (%) 69 (24.2) 22 (12) 0.004
Complete RBBB, n (%) 11 (3.9) 5 (3) 0.794
QRS >110 ms in V1 to V3, n (%) 102 (36.3) 61 (36.7) 0.924
Family history of SCD/SVT/VF, n (%) 25 (8.8) 23 (12.6) 0.187
b-Blocker therapy, n (%) 252 (88.4) 131 (71.6) 0.103
ACEI therapy, n (%) 226 (80.1) 131 (71.6) 0.395
LVEF indicates left ventricular ejection fraction; LVEDD, left ventricular end-diastolic diameter; LBBB, left bundle branch block; RBBB, right bundle branch block; SCD/SVT/VF, sudden
cardiac death, sustained ventricular tachycardia, and ventricular ﬁbrillation; ACEI, angiotensin-converting enzyme inhibitor;
*Between groups.
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these data, we suggest that a comprehensive evaluation of
DCM patients by Holter monitoring and family history, with
particular attention to SCD, will improve the prognostic
stratiﬁcation and the global management of DCM patients.
The subgroup of overall DCM patients who have an AR-DCM
phenotype should be considered at increased risk of future
events compared with the remaining DCM group. The
possible genetic overlap with other arrhythmogenic car-
diomyopathies, such as ARVC, left-dominant arrhythmogenic
cardiomyopathy, and channelopathies, needs to be further
explored.
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